X
No Ads. No Trackers. No Kidding! (Learn More)
Loading...
How can AEPi's leadership be connected with an organization that affiliates with individuals who want to see the demise of the Jewish people. [Read More]
Thumbnail
People's lives—and the full reopening of the economy—depend on rolling out the Covid-19 vaccines as quickly as possible. 5 possible ideas. [Read More]
It has been just over a month since the U.S. began the most sweeping mass vaccination campaign in its history, and progress is already lagging... [Read More]
Thumbnail
Calling the Covid-19 vaccine rollout a "dismal failure thus far," President-elect Joe Biden unveiled the outlines of a plan to bolster the vaccination effort. [Read More]
Text size ... [Read More]
Thumbnail
Jefferies analyst David Windley has cast some doubt on investors' belief that the incoming Biden administration will greatly expand government healthcare... [Read More]
Anthem could benefit as the labor market recovers, says Jefferies. ... [Read More]
Thumbnail
Results of a large Phase 3 trial are expected in the coming weeks. It is expected to show the single-dose vaccine is very effective, if... [Read More]
Thumbnail
The company is behind schedule to meet commitments made to Operation Warp Speed, the newspaper said. [Read More]
Text size ... [Read More]
One analyst estimates that the deal could add $1.6 billion to the biotech's revenue. The deal gives the drug an effective price of $2,100 a... [Read More]
Chief Scientific Officer Mikael Dolsten says that Pfizer is working on a more stable formulation of its Covid-19 vaccine that will be easier to distribute. [Read More]
The comments highlight what is slowly becoming a consensus among experts: People may need to get regularly vaccinated against Covid-19 for years. [Read More]
Company CEO Alex Gorsky said at a conference that the company is in the "final stages" of analyzing the single-dose vaccine's efficacy. [Read More]
Half of the patients hospitalized with Covid-19 are receiving remdesivir, which is sold as Veklury, according to CEO Daniel O'Day. [Read More]
Text size ... [Read More]
The stock rose, as did shares of Biogen, which is developing a separate treatment. Lilly said its experimental drug slowed the cognitive decline of... [Read More]
Eli Lilly stock is up almost 20% over the past 12 months. ... [Read More]
The stock has dropped 46.4% over the past year even as the S&P 500 Health Care sector index has climbed 14.2%. [Read More]
test tubes Dreamstime ... [Read More]
Loading...
Save As
Preview
Preview